Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform.

ABSTRACT:

Background

Next generation sequencing tests (NGS) are usually performed on relatively small core biopsy or fine needle aspiration (FNA) samples. Data is limited on what amount of tumor by volume or minimum number of FNA passes are needed to yield sufficient material for running NGS. We sought to identify the amount of tumor for running the PCDx NGS platform.

Methods

2,723 consecutive tumor tissues of all cancer types were queried and reviewed for inclusion. Information on tumor volume, success of performing NGS, and results of NGS were compiled. Assessment of sequence analysis, mutation calling and sensitivity, quality control, drug associations, and data aggregation and analysis were performed.

Results

6.4% of samples were rejected from all testing due to insufficien

SUBMITTER: Morris SM 

PROVIDER: S-EPMC5922576 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature